<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04569916</url>
  </required_header>
  <id_info>
    <org_study_id>IIT-RT-IRI-SHR1210-APA</org_study_id>
    <nct_id>NCT04569916</nct_id>
  </id_info>
  <brief_title>Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors</brief_title>
  <official_title>An Exploratory Study to Evaluate Radiotherapy Combined With Irinotecan Liposome and Apatinib Followed by PD-1 Antibody and Apatinib for the Treatment of Advanced Solid Tumors That Failed Standard Treatments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An exploratory study to evaluate for the treatment of advanced solid tumors that failed&#xD;
      standard treatments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single-arm, observational study. After the subjects meet the inclusive&#xD;
      and exclusive criteria, then they will receive radiotherapy combined with irinotecan liposome&#xD;
      and apatinib followed by PD-1 antibody and apatinib.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluated by researchers based on the RECIST 1.1 standard</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluated by researchers based on the RECIST 1.1 standard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluated by researchers based on the RECIST 1.1 standard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between immune microenvironment parameters of target lesions and efficacy</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluated by researchers based on the RECIST 1.1 standard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug-related Adverse Event</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluated by researchers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug-related Serious Adverse Event</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluated by researchers</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib</description>
    <arm_group_label>treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan liposome</intervention_name>
    <description>radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib</description>
    <arm_group_label>treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>apatinib</intervention_name>
    <description>radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib</description>
    <arm_group_label>treatment group</arm_group_label>
    <other_name>Apatinib Mesylate Tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1 antibody</intervention_name>
    <description>radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib</description>
    <arm_group_label>treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18-70 years old, both men and women;&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group performance status 0-1;&#xD;
&#xD;
          3. Pathologically confirmed recurrent or metastatic solid tumors (pancreatic cancer,&#xD;
             colorectal cancer, non-small cell lung cancer, hepatocellular carcinoma, head and neck&#xD;
             tumors, gastric cancer, etc.) that failed, couldn't tolerate or lacked standard&#xD;
             treatments;&#xD;
&#xD;
          4. According to the response evaluation criteria in solid tumor (RECIST 1.1), at least&#xD;
             two measurable lesion for radiotherapy; for patients with brain metastases, there must&#xD;
             be at least one metastasis outside the brain;&#xD;
&#xD;
          5. Expected survival period ≥ 12 weeks;&#xD;
&#xD;
          6. The main organ function and bone marrow function are normal, meeting the following&#xD;
             requirements:&#xD;
&#xD;
               1. Hemoglobin ≥ 90 g / L; (No blood transfusion within 14 days)&#xD;
&#xD;
               2. Absolute neutrophil count ≥1.5×109/L;&#xD;
&#xD;
               3. platelet count ≥ 90 × 109 / L;&#xD;
&#xD;
               4. Total bilirubin ≤ 1.5 times the upper limit of normal (ULN)&#xD;
&#xD;
               5. alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times&#xD;
                  ULN; if there is liver metastasis, ALT and AST ≤ 5 times ULN;&#xD;
&#xD;
               6. creatinine ≤ 1.5 times ULN;&#xD;
&#xD;
               7. Left ventricular ejection fraction (LVEF) ≥ 50%; QTc male &lt;450ms, female &lt;470ms;&#xD;
&#xD;
          7. Patients who have not received anticoagulant therapy have an international normalized&#xD;
             ratio (INR) of ≤1.5 and partial thromboplastin time (APTT) ≤1.5 times ULN. Patients&#xD;
             receiving total or parenteral anticoagulant therapy should be stable for at least 2&#xD;
             weeks before entering the clinical study, and the results of the coagulation test are&#xD;
             within the limits of local treatment;&#xD;
&#xD;
          8. Women of childbearing age must have a negative pregnancy test (serum or urine) within&#xD;
             14 days prior to enrollment, and voluntarily use the appropriate method for&#xD;
             contraception during the observation period and within 3 months after the last&#xD;
             administration of the study drug; for men, surgical sterilization or consent to use&#xD;
             appropriate methods of contraception during the observation period and within 3 months&#xD;
             after the last administration of the study drug.&#xD;
&#xD;
          9. The toxicity of receiving pre-treatment has been restored to ≤grade 1 (if the patient&#xD;
             received surgery, the wound should be completely healed);&#xD;
&#xD;
         10. Patients voluntarily participate in and sign informed consent, and they are expected&#xD;
             to have good compliance and can cooperate with the research according to the program&#xD;
             requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received any kind of anti-tumor treatment within 4 weeks before enrollment, including&#xD;
             radiotherapy, chemotherapy, molecular targeted therapy, and immunotherapy, or&#xD;
             participate in another interventional clinical trial;&#xD;
&#xD;
          2. Major surgery was performed within 4 weeks before enrollment (except for minor&#xD;
             surgery, such as placement of vascular access); surgical fixation of the bone lesions&#xD;
             to be irradiated is required, and mechanical stabilization is indicated;&#xD;
&#xD;
          3. There is a third interstitial fluid (such as a large amount of pleural effusion or&#xD;
             ascites) that has clinical symptoms and cannot be controlled by drainage or other&#xD;
             methods;&#xD;
&#xD;
          4. Even after medical treatment, hypertension is still poorly controlled (continuous&#xD;
             increase in systolic blood pressure ≥150mmHg or diastolic blood pressure ≥100mmHg)&#xD;
&#xD;
          5. Suffering from uncontrolled clinical symptoms or diseases of the heart, such as (1)&#xD;
             New York Heart Association II and above heart failure; (2) unstable angina; (3)&#xD;
             myocardial infarction within 1 year; (4) clinically significant patients with&#xD;
             supraventricular or ventricular arrhythmia requiring clinical intervention;&#xD;
&#xD;
          6. Patients with any active autoimmune disease or history of autoimmune disease,&#xD;
             including interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary&#xD;
             inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, and hypothyroidism&#xD;
             (hypothyroidism can be included after hormone replacement therapy), except for&#xD;
             patients with vitiligo or childhood asthma that has been completely relieved and does&#xD;
             not require any intervention after adulthood. Asthma that requires intermittent use of&#xD;
             bronchodilators or other medical intervention should also be excluded.&#xD;
&#xD;
          7. People with congenital or acquired immune function defects, such as human&#xD;
             immunodeficiency virus (HIV) infection, active hepatitis B (HBV DNA ≥ 500 IU/ml),&#xD;
             hepatitis C (hepatitis C antibody positive, and HCV-RNA is higher than the lower limit&#xD;
             of the analytical method) or co-infection with hepatitis B and C;&#xD;
&#xD;
          8. Severe infection within 4 weeks before the first dose (eg, intravenous infusion of&#xD;
             antibiotics, antifungal or antiviral drugs), or unexplained fever &gt;38.5 °C during&#xD;
             screening/before first dose;&#xD;
&#xD;
          9. Events of arterial or venous thrombosis occurring within 6 months before enrollment,&#xD;
             such as cerebrovascular accidents (including transient ischemic attacks, cerebral&#xD;
             hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism;&#xD;
&#xD;
         10. Have had or have other systemic malignancies in the last 5 years (except for cured&#xD;
             skin basal cell carcinoma and cervical carcinoma in situ and ovarian cancer);&#xD;
&#xD;
         11. Those who are known to be allergic to any study drug;&#xD;
&#xD;
         12. Pregnant patients, lactating patients, or patients with reproductive ability are not&#xD;
             willing to take effective contraceptive measures;&#xD;
&#xD;
         13. Have a clear history of neurological or mental disorders, including epilepsy and&#xD;
             dementia;&#xD;
&#xD;
         14. Known uncontrolled or symptomatic active central nervous system (CNS) metastases,&#xD;
             manifested by clinical signs, cerebral edema, spinal cord compression, cancerous&#xD;
             meningitis, pia mater disease, and/or progressive growth;&#xD;
&#xD;
         15. Patients who are unable to swallow the study drug, such as patients with chronic&#xD;
             diarrhea (including but not limited to irritable bowel syndrome, Crohn's disease,&#xD;
             ulcerative colitis), intestinal obstruction, and other various factors that affect&#xD;
             drug administration and absorption;&#xD;
&#xD;
         16. Other circumstances that the investigator believes are not suitable for inclusion. If&#xD;
             accompanied by family or social factors, it will affect the safety of the subject or&#xD;
             the collection of data and samples.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baorui Baorui Liu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanjing Drum Tower Hospital, The Affiliated of Nanjing University Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Shen, Doctor</last_name>
    <phone>13675101127</phone>
    <email>shenjie2008nju@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital, The Affiliated of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jie Shen, Doctor</last_name>
      <phone>13675101127</phone>
      <email>shenjie2008nju@163.com</email>
    </contact>
    <investigator>
      <last_name>Baorui Liu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 24, 2020</study_first_submitted>
  <study_first_submitted_qc>September 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2020</study_first_posted>
  <last_update_submitted>September 24, 2020</last_update_submitted>
  <last_update_submitted_qc>September 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</investigator_affiliation>
    <investigator_full_name>Baorui Liu</investigator_full_name>
    <investigator_title>chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Apatinib</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to make individual participant data (IPD) available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

